AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25411281 — intervention group
Group type: EXPERIMENTAL
Intervention: Discovery GWA analysis
Number of subjects: 2403
Study 25411281 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-stage analysis
Number of subjects: 2403
Study 25411597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 12.5 mg
Number of subjects: 361
Study 25411597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 25 mg
Number of subjects: 361
Study 25411597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 361
Study 25411597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg
Number of subjects: 361
Study 25411597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 25411597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin (all doses)
Number of subjects: 361
Study 25411598 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble β-1,3/1,6-glucan (SBG)
Number of subjects: 60
Study 25411598 — intervention group
Group type: COMPARATOR
Intervention: methylcellulose (control)
Number of subjects: 60
Study 25411804 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated scoring using ApneaLink Plus monitor
Number of subjects: 200
Study 25411804 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated scoring using Embletta monitor
Number of subjects: 200
Study 25411804 — intervention group
Group type: COMPARATOR
Intervention: Manual scoring
Number of subjects: 200
Study 25411976 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 82
Study 25412225 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral infection during exacerbations
Number of subjects: 119
Study 25412225 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-positive exacerbations
Number of subjects: 119
Study 25412225 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum interferon-γ-induced protein 10
Number of subjects: 119
Study 25412225 — intervention group
Group type: EXPERIMENTAL
Intervention: IV antibiotics
Number of subjects: 119
Study 25413133 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of NO and oxygen
Number of subjects: 16
Study 25413133 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal bicycle exercise
Number of subjects: 16
Study 25413133 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 16
Study 25413133 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 16
Study 25413378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 260
Study 25413378 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 260
Study 25413378 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG variables (general)
Number of subjects: 260
Study 25413378 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG variables (specific)
Number of subjects: 260
Study 25414187 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera-connected prosthesis (Argus II)
Number of subjects: 3
Study 25415228 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT1/2 inhibitor (AR-C155858)
Number of subjects: 2
Study 25415228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligomycin A (inhibitor of mitochondrial ATP synthase)
Number of subjects: 2
Study 25415228 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study 25416075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 87
Study 25416075 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant soy porridge
Number of subjects: 87
Study 25416418 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management strategies for CKD
Number of subjects: 34
Study 25416418 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care providers' awareness of treatment burden
Number of subjects: 34
Study 25416753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of wild-type A(H1N1)pdm09 virus at an optimal dose of 10(7) tissue culture infectious dose 50.
Number of subjects: 69
Study 25416753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of wild-type A(H1N1)pdm09 virus.
Number of subjects: 69
Study 25416807 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab therapy
Number of subjects: 0
Study 25416917 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week nutritional intervention promoting the Mediterranean diet (MedDiet) based on Self-Determination Theory (SDT)
Number of subjects: 123
Study 25417733 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy total dose with target volumes defined on pre-RT FDG-PET/CT
Number of subjects: 10
Study 25417733 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy with boost target volume defined on FDG-PET/CT during RT
Number of subjects: 10
Study 25417733 — intervention group
Group type: EXPERIMENTAL
Intervention: 66 Gy with target volumes from pre-RT FDG-PET/CT
Number of subjects: 10
Study 25417733 — intervention group
Group type: EXPERIMENTAL
Intervention: 66 Gy with boost target volume from during-RT FDG-PET/CT
Number of subjects: 10
Study 25417733 — intervention group
Group type: EXPERIMENTAL
Intervention: During-RT FDG-PET/CT
Number of subjects: 10
Study 25417733 — intervention group
Group type: EXPERIMENTAL
Intervention: 66 Gy planning on during-RT PET
Number of subjects: 10
Study 25417902 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg/afuresertib 50 mg once daily continuously
Number of subjects: 20
Study 25417902 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg/afuresertib 25 mg
Number of subjects: 20
Study 25417902 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 1.0 mg/afuresertib 50 mg
Number of subjects: 20
Study 25417902 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg (continuous)/afuresertib 50 mg (Days 1-10 every 28 days)
Number of subjects: 20
Study 25417902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trametinib and afuresertib
Number of subjects: 20
Study 25417909 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment (AT)
Number of subjects: 116
Study 25417940 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulating access to secondary and tertiary care and restricting free provider choice to the primary care level.
Number of subjects: 0
Study 25417940 — intervention group
Group type: COMPARATOR
Intervention: Unregulated access to health-care services.
Number of subjects: 0
Study 25418910 — intervention group
Group type: EXPERIMENTAL
Intervention: LVR-coil treatment
Number of subjects: 38
Study 25419693 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell reconstitution following haploidentical BM transplantation and post-transplant CY
Number of subjects: 0
Study 25419882 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic adrenal insufficiency receiving follow-up questionnaires and phone contact for reported adrenal crisis.
Number of subjects: 423
Study 25420620 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric sorting of human sperm (MicroSort®)
Number of subjects: 4993
Study 25420620 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI (Intrauterine Insemination)
Number of subjects: 4993
Study 25420620 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF/ICSI (In Vitro Fertilization/Intracytoplasmic Sperm Injection)
Number of subjects: 4993
Study 25420620 — intervention group
Group type: EXPERIMENTAL
Intervention: FET (Frozen Embryo Transfer)
Number of subjects: 4993
Study 25421091 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/infusion of recombinant human sulphamidase (rhSGSH)
Number of subjects: 0
Study 25421091 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/infusion of recombinant human sulphamidase (rhSGSH)
Number of subjects: 0
Study 25421091 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/infusion of recombinant human sulphamidase (rhSGSH) at fortnightly intervals
Number of subjects: 0
Study 25421091 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/infusion of recombinant human sulphamidase (rhSGSH) at monthly intervals
Number of subjects: 0
Study 25421091 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/infusion of recombinant human sulphamidase (rhSGSH) at fortnightly intervals
Number of subjects: 0
Study 25421474 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine treatment regimen
Number of subjects: 1806
Study 25422275 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium (558 patients)
Number of subjects: 1112
Study 25422275 — intervention group
Group type: COMPARATOR
Intervention: No delirium (554 patients)
Number of subjects: 1112
Study 25422275 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium lasting 2 days or more (post hoc analysis)
Number of subjects: 1112
Study 25422275 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium of any duration (competing risk analysis)
Number of subjects: 1112
Study 25422771 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride/metformin fixed-dose combination (G/M FDC)
Number of subjects: 209
Study 25422771 — intervention group
Group type: COMPARATOR
Intervention: Metformin uptitration (Met UP)
Number of subjects: 209
Study 25423261 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS (overweight/obese)
Number of subjects: 422
Study 25423261 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS (lean)
Number of subjects: 422
Study 25423261 — intervention group
Group type: COMPARATOR
Intervention: Women without PCOS (overweight/obese)
Number of subjects: 422
Study 25423261 — intervention group
Group type: COMPARATOR
Intervention: Women without PCOS (lean)
Number of subjects: 422
Study 25423261 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 422
Study 25423261 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 422
Study 25423261 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin to leptin ratios
Number of subjects: 422
Study 25424529 — intervention group
Group type: EXPERIMENTAL
Intervention: High Wells score (>4)
Number of subjects: 79
Study 25424529 — intervention group
Group type: COMPARATOR
Intervention: Low Wells score (≤4)
Number of subjects: 79
Study 25424783 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 1040
Study 25424783 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A control vaccine
Number of subjects: 1040
Study 25424792 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0
Study 25424932 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix™ (2 doses)
Number of subjects: 2348
Study 25424933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (RVGE)
Number of subjects: 758
Study 25424933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydration
Number of subjects: 758
Study 25424933 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of GE
Number of subjects: 758
Study 25424933 — intervention group
Group type: EXPERIMENTAL
Intervention: RV strain G1WTP[8]WT
Number of subjects: 758
Study 25425121 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa (0.2 mg/kg, intravenous, every-other-week)
Number of subjects: 11
Study 25425121 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa
Number of subjects: 11
Study 25425230 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Induced Coagulopathy Clinical Score (TICCS)
Number of subjects: 82
Study 25425230 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients not needing DCR)
Number of subjects: 82
Study 25425411 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Released Stabilized (CRS) socket
Number of subjects: 2
Study 25425411 — intervention group
Group type: COMPARATOR
Intervention: Traditional transhumeral (TH) socket
Number of subjects: 2
Study 25425683 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric immunophenotyping of bone marrow
Number of subjects: 81
Study 25425683 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric abnormalities in children with refractory cytopenia
Number of subjects: 81
Study 25425684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone
Number of subjects: 0
Study 25425684 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexamethasone
Number of subjects: 0
Study 25426451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal Interposition coupled with Sleeve Gastrectomy (IISG)
Number of subjects: 75
Study 25426451 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverted Sleeve Gastrectomy (IIDSG)
Number of subjects: 75
Study 25426701 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 3
Study 25426701 — intervention group
Group type: COMPARATOR
Intervention: Biphasic human insulin 30 (BHI)
Number of subjects: 3
Study 25426701 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 3
Study 25426701 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) insulin
Number of subjects: 3
Study 25426834 — intervention group
Group type: EXPERIMENTAL
Intervention: cAd3-EBO vaccine (2×10^11 viral particles)
Number of subjects: 20
Study 25427282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 41
Study 25427521 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Number of subjects: 35
Study 25427521 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data comparison between responders and non-responders
Number of subjects: 35
Study 25427521 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study results
Number of subjects: 35
Study 25428504 — intervention group
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Number of subjects: 0
Study 25428602 — intervention group
Group type: EXPERIMENTAL
Intervention: RESOLUTE zotarolimus-eluting stent (R-ZES)
Number of subjects: 165
Study 25428650 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF biologicals (infliximab and adalimumab)
Number of subjects: 0
Study 25428714 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood ZPP
Number of subjects: 470
Study 25428714 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte ZPP
Number of subjects: 470
Study 25428714 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte protoporphyrin
Number of subjects: 470
Study 25428714 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ZPP with haemoglobin concentration
Number of subjects: 470
Study 25428714 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cut off points for whole blood ZPP (>70 μmol/mol haem)
Number of subjects: 470
Study 25428714 — intervention group
Group type: EXPERIMENTAL
Intervention: ZPP
Number of subjects: 470
Study 25428822 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endovascular therapy
Number of subjects: 1179
Study 25428822 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endovascular therapy (within 180-270 min)
Number of subjects: 1179
Study 25428822 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endovascular therapy (severe strokes)
Number of subjects: 1179
Study 25428822 — intervention group
Group type: COMPARATOR
Intervention: Endovascular thrombectomy
Number of subjects: 1179
Study 25429097 — intervention group
Group type: EXPERIMENTAL
Intervention: Short resaturation schedule (15 s)
Number of subjects: 47
Study 25429097 — intervention group
Group type: COMPARATOR
Intervention: Long resaturation schedule (90 s)
Number of subjects: 47
Study 25429097 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 47
Study 25429244 — intervention group
Group type: EXPERIMENTAL
Intervention: High protocol use ICUs
Number of subjects: 0
Study 25429244 — intervention group
Group type: COMPARATOR
Intervention: Low protocol use ICUs
Number of subjects: 0
Study 25429521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K antagonists
Number of subjects: 1019
Study 25429526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² plus cisplatin 70 mg/m² on day 1 every 3 weeks
Number of subjects: 42
Study 25429526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 42
Study 25430934 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT Neuropathy Score (CMTNS)
Number of subjects: 1652
Study 25430934 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT Examination Score (CMTES)
Number of subjects: 1652
Study 25430934 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic diagnosis
Number of subjects: 1652
Study 25430934 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT subtypes distribution
Number of subjects: 1652
Study 25430947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular IFN-β-1a autoinjector
Number of subjects: 232
Study 25431308 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU
Number of subjects: 282
Study 25431308 — intervention group
Group type: COMPARATOR
Intervention: OT
Number of subjects: 282
Study 25431308 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult airway management techniques in OT
Number of subjects: 282
Study 25431308 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult airway management techniques in ICU
Number of subjects: 282
Study 25431439 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and activity modification
Number of subjects: 120
Study 25431439 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic surgery
Number of subjects: 120
Study 25431460 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure time physical activity (LTPA)
Number of subjects: 236
Study 25431460 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised resistance exercise (RE)
Number of subjects: 236
Study 25431460 — intervention group
Group type: COMPARATOR
Intervention: Supervised resistance exercise program (REP)
Number of subjects: 236
Study 25432093 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis implantation
Number of subjects: 0
Study 25432172 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic inhibition of Akt
Number of subjects: 0
Study 25432492 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric balanced diet (HBD) for 12 weeks
Number of subjects: 44
Study 25432532 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency video capsule endoscopy (VCE)
Number of subjects: 20
Study 25432592 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous blood lactate (VBL)
Number of subjects: 103
Study 25432592 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial blood lactate (ABL)
Number of subjects: 103
Study 25432592 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood lactate (CBL)
Number of subjects: 103
Study 25432592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at 28 days
Number of subjects: 103
Study 25432592 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial blood lactate, VBL, and CBL
Number of subjects: 103
Study 25432718 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized research-based strategy for HA case management
Number of subjects: 3
Study 25432718 — intervention group
Group type: COMPARATOR
Intervention: Regular routine in relation to HA
Number of subjects: 3
Study 25433216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a+Vi
Number of subjects: 0
Study 25433216 — intervention group
Group type: COMPARATOR
Intervention: Ty21a
Number of subjects: 0
Study 25433216 — intervention group
Group type: COMPARATOR
Intervention: Vi
Number of subjects: 0
Study 25433628 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis continued until age 4 years (n=45)
Number of subjects: 203
Study 25433628 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole prophylaxis discontinued at age 2 years (n=46)
Number of subjects: 203
Study 25433628 — intervention group
Group type: COMPARATOR
Intervention: HIV-exposed children who stopped co-trimoxazole at age 4 years
Number of subjects: 203
Study 25433628 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected children on continuous co-trimoxazole prophylaxis (n=48)
Number of subjects: 203
Study 25433628 — intervention group
Group type: COMPARATOR
Intervention: HIV-unexposed uninfected children (n=100)
Number of subjects: 203
Study 25433674 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Camp Intervention (HC) group
Number of subjects: 246
Study 25433674 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) exercise group
Number of subjects: 246
Study 25435055 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite incident HPV infection of the anus
Number of subjects: 200
Study 25435055 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible HPV infections in the anus
Number of subjects: 200
Study 25435055 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite incident HPV infection on the penis
Number of subjects: 200
Study 25435055 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible HPV infections on the penis
Number of subjects: 200
Study 25435055 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite incident HPV infection in the mouth
Number of subjects: 200
Study 25435055 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV types in the quadrivalent vaccine (anal)
Number of subjects: 200
Study 25435055 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV types in the quadrivalent vaccine (penile)
Number of subjects: 200
Study 25435055 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission probability from penis to anus
Number of subjects: 200
Study 25435886 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 22
Study 25435886 — intervention group
Group type: COMPARATOR
Intervention: placebo/no treatment
Number of subjects: 22
Study 25436806 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib treatment
Number of subjects: 32
Study 25436806 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping crizotinib
Number of subjects: 32
Study 25438151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103 (LGG) 1×10^10 CFU, orally, twice daily for 28 days
Number of subjects: 15
Study 25438151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103 (LGG)
Number of subjects: 15
Study 25439094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction (executive or memory dysfunction)
Number of subjects: 613